Literature DB >> 31769183

Evidence on the causal link between homocysteine and hypertension from a meta-analysis of 40 173 individuals implementing Mendelian randomization.

Liwan Fu1, Ya-Nan Li1, Dongmei Luo1,2, Shufang Deng1, Baihui Wu1, Yue-Qing Hu1,3.   

Abstract

Numerous researchers have investigated the associations among methylenetetrahydrofolate reductase gene (MTHFR) C677T polymorphism, homocysteine (Hcy) concentration, and hypertension. However, the results are controversial. Thus, a meta-analysis implementing Mendelian randomization approach was conducted to examine the hypothesis that elevated Hcy concentration plausibly contributes to increased risk of hypertension. Based on several inclusion and exclusion criteria, eligible studies were selected to explore the correlation between MTHFR C677T and hypertension risk, MTHFR C677T and Hcy concentration in hypertension, and Hcy concentration and hypertension, and they were evaluated by odds ratios (ORs), effect size (ES), and standard mean difference with their corresponding 95% confidence intervals (95% CIs), respectively. Moreover, Mendelian randomization was implemented to evaluate the relationship between Hcy and hypertension. Consequently, 14 378 cases and 25 795 controls were involved in this study and the results showed that MTHFR C677T led to an elevated risk of hypertension (for T vs C: OR = 1.27, 95% CI = 1.17-1.37; for TT vs CC: OR = 1.53, 95% CI = 1.30-1.79). Additionally, in hypertensive subjects, the pooled Hcy concentration in individuals of TT genotype was 7.74 μmol/L (95% CI: 5.25-10.23) greater than that in individuals of CC genotype. Moreover, the pooled Hcy concentration in hypertensive was 0.69 μmol/L (95% CI: 0.50-0.87) greater than that in controls. The estimated causal OR associated with hypertension was 1.32 for 5 μmol/L Hcy increment. Via MTHFR C677T polymorphism, the findings in the present study demonstrated that there exists evidence on causal link between Hcy concentration and the risk of hypertension.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  zzm321990MTHFRzzm321990; homocysteine; hypertension; polymorphism

Mesh:

Substances:

Year:  2019        PMID: 31769183      PMCID: PMC8030561          DOI: 10.1111/jch.13737

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  111 in total

Review 1.  Genetic associations in large versus small studies: an empirical assessment.

Authors:  John P A Ioannidis; Thomas A Trikalinos; Evangelia E Ntzani; Despina G Contopoulos-Ioannidis
Journal:  Lancet       Date:  2003-02-15       Impact factor: 79.321

2.  Methylenetetrahydrofolate reductase 677 C --> T polymorphism, plasma folate, vitamin B(12) concentrations, and risk of preeclampsia among black African women from Zimbabwe.

Authors:  A Rajkovic; K Mahomed; R Rozen; M R Malinow; I B King; M A Williams
Journal:  Mol Genet Metab       Date:  2000-01       Impact factor: 4.797

3.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

4.  A case-control study of the association between the MTHFR gene and essential hypertension in Asian Indians.

Authors:  A Poduri; S Kumari; S Jain; M Khullar
Journal:  J Hum Hypertens       Date:  2008-08-28       Impact factor: 3.012

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  Methylenetetrahydrofolate reductase polymorphism, folate, and susceptibility to preeclampsia.

Authors:  R W Powers; L A Minich; D L Lykins; R B Ness; W R Crombleholme; J M Roberts
Journal:  J Soc Gynecol Investig       Date:  1999 Mar-Apr

7.  [A case-control study on the relationship between abnormal homocysteine metabolism and essential hypertension].

Authors:  S Zhan; Y Gao; X Yin; Y Huang; Y Hu; L Li
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2000-06

8.  The effect of methylenetetrahydrofolate reductase C677T common variant on hypertensive risk is not solely explained by increased plasma homocysteine values.

Authors:  Francisco Rodríguez-Esparragón; Octavio Hernández-Perera; José C Rodríguez-Pérez; Aránzazu Anábitarte; Juan M Díaz-Cremades; Antonio Losada; Dolores Fiuza; Enrique Hernández; Carla Yunis; Carlos M Ferrario
Journal:  Clin Exp Hypertens       Date:  2003-05       Impact factor: 1.749

9.  Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations.

Authors:  Toshiko Tanaka; Paul Scheet; Betti Giusti; Stefania Bandinelli; Maria Grazia Piras; Gianluca Usala; Sandra Lai; Antonella Mulas; Anna Maria Corsi; Anna Vestrini; Francesco Sofi; Anna Maria Gori; Rosanna Abbate; Jack Guralnik; Andrew Singleton; Goncalo R Abecasis; David Schlessinger; Manuela Uda; Luigi Ferrucci
Journal:  Am J Hum Genet       Date:  2009-03-19       Impact factor: 11.025

10.  Plausible relationship between homocysteine and obesity risk via MTHFR gene: a meta-analysis of 38,317 individuals implementing Mendelian randomization.

Authors:  Liwan Fu; Ya-Nan Li; Dongmei Luo; Shufang Deng; Yue-Qing Hu
Journal:  Diabetes Metab Syndr Obes       Date:  2019-07-23       Impact factor: 3.168

View more
  11 in total

Review 1.  Methylenetetrahydrofolate Reductase Polymorphism (rs1801133) and the Risk of Hypertension among African Populations: A Narrative Synthesis of Literature.

Authors:  Sihle E Mabhida; Babu Muhamed; Jyoti R Sharma; Teke Apalata; Sibusiso Nomatshila; Lawrence Mabasa; Mongi Benjeddou; Charity Masilela; Khanyisani Ziqubu; Samukelisiwe Shabalala; Rabia Johnson
Journal:  Genes (Basel)       Date:  2022-04-01       Impact factor: 4.141

2.  Evidence on the causal link between homocysteine and hypertension from a meta-analysis of 40 173 individuals implementing Mendelian randomization.

Authors:  Liwan Fu; Ya-Nan Li; Dongmei Luo; Shufang Deng; Baihui Wu; Yue-Qing Hu
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-11-25       Impact factor: 3.738

3.  Apply multiple genetic variants as instrumental variables-Response to "MTHFR C677T polymorphism and hypertension".

Authors:  Liwan Fu; Yue-Qing Hu
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-19       Impact factor: 3.738

4.  MTHFR C677T polymorphism and hypertension.

Authors:  Pathum Sookaromdee; Viroj Wiwanitkit
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-19       Impact factor: 3.738

5.  The association between retinal vessel abnormalities and H-type hypertension.

Authors:  Kuankuan Huang; Zhixiang Zhang; Shan Huang; Yanwen Jia; Min Zhang; Wenwei Yun
Journal:  BMC Neurol       Date:  2021-01-06       Impact factor: 2.474

6.  Effect of interaction between occupational stress and polymorphisms of MTHFR gene and SELE gene on hypertension.

Authors:  Fen Yang; Ruiying Qiu; Saimaitikari Abudoubari; Ning Tao; Hengqing An
Journal:  PeerJ       Date:  2022-02-16       Impact factor: 2.984

Review 7.  Association Between MTHFR Polymorphisms and the Risk of Essential Hypertension: An Updated Meta-analysis.

Authors:  Hao Meng; Shaoyan Huang; Yali Yang; Xiaofeng He; Liping Fei; Yuping Xing
Journal:  Front Genet       Date:  2021-11-26       Impact factor: 4.599

8.  Association of ALDH2 rs671 and MTHFR rs1801133 polymorphisms with hypertension among Hakka people in Southern China.

Authors:  Heming Wu; Qingyan Huang; Zhikang Yu; Zhixiong Zhong
Journal:  BMC Cardiovasc Disord       Date:  2022-03-27       Impact factor: 2.298

9.  The association of MTHFR (rs1801133) with hypertension in an indigenous south African population.

Authors:  Sihle E Mabhida; Jyoti R Sharma; Teke Apalata; Charity Masilela; Sibusiso Nomatshila; Lawrence Mabasa; Hannah Fokkens; Mongi Benjeddou; Babu Muhamed; Samukelisiwe Shabalala; Rabia Johnson
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

10.  Homocysteine predicts vascular target organ damage in hypertension and may serve as guidance for first-line antihypertensive therapy.

Authors:  Revathy Carnagarin; Janis M Nolde; Natalie C Ward; Leslie Marisol Lugo-Gavidia; Justine Chan; Sandi Robinson; Ancy Jose; Anu Joyson; Omar Azzam; Márcio Galindo Kiuchi; Bibombe P Mwipatayi; Markus P Schlaich
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-06-17       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.